†A Cross-Study Comparison Investigating the Effect of CSL112 (Apolipoprotein A-I [Human]) on Cholesterol Efflux Capacity (Encore ACC 2022)

Mace Pharmacodynamics
DOI: 10.1016/j.jacl.2022.05.035 Publication Date: 2022-08-10T07:18:13Z